NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00015-3210-30 | 00015-3210 | Carboplatin | Paraplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 1, 2007 | Sep 30, 2008 | In Use | |
00143-9547-01 | 00143-9547 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
00555-0887-14 | 00555-0887 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 28, 1997 | Jan 26, 2011 | In Use | |
00078-0916-61 | 00078-0916 | Letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
55150-0299-01 | 55150-0299 | Fosaprepitant dimeglumine | Fosaprepitant dimeglumine | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jan 12, 2021 | In Use | |
51144-0030-01 | 51144-0030 | ENFORTUMAB VEDOTIN | PADCEV | 30.0 mg/3mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec 18, 2019 | In Use | |
00003-0528-11 | 00003-0528 | Dasatinib | Sprycel | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 27, 2006 | In Use | |
59212-0700-12 | 59212-0700 | Prednisolone Sodium Phosphate | Orapred ODT | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 30, 2020 | In Use | |
63187-0265-60 | 63187-0265 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jul 3, 2017 | In Use | |
65862-0149-05 | 65862-0149 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 30, 2007 | In Use | |
65862-0188-99 | 65862-0188 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
00069-0298-60 | 00069-0298 | Glasdegib | Daurismo | 25.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec 10, 2018 | In Use | |
00591-0528-05 | 00591-0528 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Mar 14, 1996 | Dec 31, 2017 | In Use | |
25021-0816-30 | 25021-0816 | Leucovorin Calcium | Leucovorin Calcium | 350.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Sep 15, 2012 | In Use | |
00378-6678-28 | 00378-6678 | Sunitinib malate | Sunitinib Malate | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Jan 4, 2022 | In Use | |
55513-0098-01 | 55513-0098 | Darbepoetin alfa | Aranesp | 10.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Oct 6, 2015 | In Use | ||
50090-1523-01 | 50090-1523 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Human Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | In Use | |
70860-0201-10 | 70860-0201 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Mar 15, 2017 | In Use | |
00143-9387-25 | 00143-9387 | Triamcinolone Acetonide | Triamcinolone Acetonide | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | Mar 3, 2025 | In Use | |
71332-0006-90 | 71332-0006 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jun 24, 2024 | In Use | |
16714-0137-01 | 16714-0137 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 25, 2021 | In Use | |
16714-0915-01 | 16714-0915 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 250.0 mg/25mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sep 26, 2018 | In Use | |
72374-0101-01 | 72374-0101 | Filgrastim-txid | NYPOZI | 300.0 ug/300ug | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 16, 2024 | In Use | |
75907-0059-10 | 75907-0059 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug 22, 2024 | In Use | ||
69097-0313-37 | 69097-0313 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 25, 2011 | In Use |
Found 11748 results — Export these results